TiumBio Co., Ltd. Logo

TiumBio Co., Ltd.

Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.

321550 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TiumBio Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutics for rare and incurable diseases. The company leverages its expertise in both small-molecule synthetic drugs and biologics to build a robust pipeline targeting areas with high unmet medical needs and significant growth potential. Its lead clinical programs include Merigolix (TU2670), an oral GnRH antagonist for treating gynecological conditions like endometriosis and uterine fibroids, and TU7710, a long-acting recombinant protein for hemophilia. Founded in 2016, TiumBio is also expanding its R&D capabilities into next-generation therapies, including bispecific antibodies and antibody-drug conjugates (ADCs), to create market value through its distinct portfolio.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for TiumBio Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-22 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.6 KB

Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops DNA vaccines and therapeutics for companion animals and livestock.
South Korea 222670
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530

Talk to a Data Expert

Have a question? We'll get back to you promptly.